UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000010935
Receipt No. R000012800
Scientific Title The combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with advanced non-small-cell lung cancer harboring EGFR mutations: a phase 2 trial.
Date of disclosure of the study information 2013/06/12
Last modified on 2016/06/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with advanced non-small-cell lung cancer harboring EGFR mutations: a phase 2 trial.
Acronym Pemetrexed and continued EGFR-TKIs beyond progressive disease in elderly patients with EGFR-mutant advanced NSCLC.
Scientific Title The combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with advanced non-small-cell lung cancer harboring EGFR mutations: a phase 2 trial.
Scientific Title:Acronym Pemetrexed and continued EGFR-TKIs beyond progressive disease in elderly patients with EGFR-mutant advanced NSCLC.
Region
Japan

Condition
Condition non-small-cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To assess the efficacy and safety of combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with EGFR-mutant advanced NSCLC.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Disease control rate
Key secondary outcomes Progression free survival, overall survival, adverse events

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 The combination therapy of pemetrexed and continued EGFR-TKIs in elderly patients with EGFR-mutant advanced NSCLC that has developed acquired resistance to EGFR-TKIs is assessed.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
75 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria All participants must meet the following criteria.
1: Histologically or pathologically proven non-squamous NSCLC.
2: Stage 3B, 4, or recurrence.
3: EGFR mutation positive.
4: Previously treated with EGFR-TKIs more than 8 weeks effectively (SD,PR, or CR), then acquired resistance.
5: Radiographically measurable lesion.
6: Age 75 years or older.
7: Eastern Cooperative Oncology Group (ECOG) performance status: 0-2.
8: No major organ system dysfunction.
a. White blood cell count: more than 3,000/uL.
b. Neutrophil cell count: more than 1500/uL.
c. Hemoglobin: more than 9.0 g/dL.
d. Platelet count: more than 100,000/uL.
e. Aspartate transaminase (AST), alanine transaminase(ALT): less than 2.5 times the upper limit of normal of the institutional reference range.
f. Total bilirubin: less than 1.5 times the upper limit of normal of the institutional reference range.
g. Creatinine: less than 1.2 mg/dL.
h. Creatinine clearance: more than 45 ml/min.
i. SpO2: more than 90%.
9: No interstitial lung disease.
10: Life expectancy of more than 3 months.
11: Written informed.

Key exclusion criteria Exclusion criteria are as follows
1: Symptomatic brain metastasis.
2: History of radiotherapy to primary lesion.
3: Severe and unstable medical comorbidities.
4: Difficulty in ingestion.
5: With third-space fluid to be drained.
6: Pregnant or breastfeeding women. Willing to get pregnant.
7: Contraindication for taking EGFR-TKIs.
8: Active double cancers.
9: History of severe allergy to drugs.
10: Judgment to attending physician.
Target sample size 22

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takafumi Suda
Organization Hamamatsu University School of Medicine
Division name Second Division, Department of Internal Medicine
Zip code
Address 1-20-1 Handayama, Higashi-ku, Hamamatsu-city, Japan
TEL 053-435-2111
Email suda@hama-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yusuke inoue
Organization Hamamatsu University School of Medicine
Division name Second Division, Department of Internal Medicine
Zip code
Address 1-20-1 Handayama, Higashi-ku, Hamamatsu-city, Japan
TEL 053-435-2111
Homepage URL
Email y.inoue@hama-med.ac.jp

Sponsor
Institute Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Institute
Department

Funding Source
Organization Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2013 Year 06 Month 12 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 04 Month 30 Day
Date of IRB
Anticipated trial start date
2013 Year 06 Month 12 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2013 Year 06 Month 12 Day
Last modified on
2016 Year 06 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012800

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.